Robert W. Baird Issues Pessimistic Forecast for Medtronic (NYSE:MDT) Stock Price

Medtronic (NYSE:MDT) had its target price dropped by stock analysts at Robert W. Baird from $103.00 to $100.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical technology company’s stock. Robert W. Baird’s target price would suggest a potential upside of 3.81% from the stock’s previous close.

Other analysts have also recently issued reports about the company. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Barclays reaffirmed an “overweight” rating and issued a $118.00 target price on shares of Medtronic in a research report on Wednesday. UBS Group reissued a “neutral” rating and set a $104.00 price target on shares of Medtronic in a report on Wednesday, February 4th. Needham & Company LLC upgraded shares of Medtronic from a “hold” rating to a “buy” rating and set a $121.00 price target for the company in a research report on Monday, February 9th. Finally, Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Sixteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $111.11.

Medtronic Stock Performance

Shares of MDT stock opened at $96.33 on Wednesday. The stock has a market capitalization of $123.50 billion, a price-to-earnings ratio of 25.96, a PEG ratio of 2.62 and a beta of 0.71. Medtronic has a one year low of $79.55 and a one year high of $106.33. The company’s 50-day simple moving average is $99.19 and its 200-day simple moving average is $96.58. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same period in the previous year, the company earned $1.38 earnings per share. Medtronic’s quarterly revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts anticipate that Medtronic will post 5.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medtronic

A number of institutional investors have recently added to or reduced their stakes in MDT. Cinctive Capital Management LP acquired a new position in Medtronic in the 4th quarter valued at approximately $2,019,000. Asset One Wealth Management LLC bought a new position in Medtronic in the fourth quarter worth $229,000. Boothbay Fund Management LLC boosted its stake in Medtronic by 251.5% during the fourth quarter. Boothbay Fund Management LLC now owns 9,470 shares of the medical technology company’s stock worth $910,000 after buying an additional 6,776 shares in the last quarter. Armistice Capital LLC increased its holdings in Medtronic by 2.3% in the 4th quarter. Armistice Capital LLC now owns 271,241 shares of the medical technology company’s stock valued at $26,055,000 after buying an additional 5,984 shares during the period. Finally, Bank OZK raised its stake in shares of Medtronic by 5.2% in the 4th quarter. Bank OZK now owns 14,078 shares of the medical technology company’s stock valued at $1,352,000 after buying an additional 697 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat: Medtronic topped consensus on revenue ($9.02B) and adjusted EPS ($1.36), driven by stronger demand in heart devices and diabetes, which underpins near‑term cash flow and credibility with investors. Article Title
• Positive Sentiment: Cardiovascular & ablation strength: Cardiac Ablation Solutions grew rapidly (PFA portfolio), with U.S. ablations more than doubling — a high‑growth end market boosting revenue mix and investor sentiment. Article Title
• Positive Sentiment: Regulatory and product catalysts: FDA clearances and commercial milestones — including the first U.S. surgery with the Hugo robotic system and new clearances for spine and bone‑graft uses — add new revenue levers. Article Title
• Positive Sentiment: Analyst / technical support: TD Cowen reiterated a Buy with a $119 target and technical/institutional accumulation stories argue for further upside into mid‑year. Article Title
• Neutral Sentiment: Guidance reaffirmed: Management kept FY26 EPS guidance near prior range (5.620–5.660) — in line with consensus and reducing forecast risk but offering limited upside surprise. Article Title
• Neutral Sentiment: Capital allocation & M&A: Continued buybacks/dividend support and strategic deals (CathWorks, Anteris) signal management is executing on growth and returns — longer‑term positives but not immediate catalysts. Article Title
• Negative Sentiment: Margin pressure / costs: Reported profit fell on higher costs, tariff headwinds and investment spending; adjusted margins contracted, which caps near‑term operating leverage. Article Title
• Negative Sentiment: Guidance reaction risk: Because the company only reaffirmed guidance (versus raising it), some investors sold into the print — keeping volatility intact despite the beat. Article Title

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).